ENvue Medical, Inc. Leases Disclosure
NOTE 10 – LEASES
The Company has operating lease agreements with terms up to 3 years, including car and office space leases.
The components of operating lease costs were as follows:
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Fixed lease cost | $ | 124 | $ | 61 | ||||
| Variable lease cost | 3 | 1 | ||||||
| Total net lease costs | $ | 127 | $ | 62 | ||||
The following table presents supplemental cash flows information related to the lease costs for operating leases:
| Year
Ended December 31, |
||||
| 2025 | ||||
| Cash paid for amounts included in measurement of lease liabilities: | ||||
| Operating cash flows for operating leases | $ | 85 | ||
The Company’s weighted-average remaining lease term relating to its operating leases is 2.21 years, with a weighted-average discount rate of 10%.
The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of December 31, 2025:
| 2026 | $ | 93 | ||
| 2027 | 29 | |||
| 2028 | 5 | |||
| Total undiscounted operating lease payments | 127 | |||
| Less: Imputed interest | 10 | |||
| Present value of operating lease liabilities | $ | 117 |
Sales-type Lease
Revenue from sales-type leases is presented on a gross basis when the Company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. The Company’s leases generally do not provide for a residual value guarantee. The Company’s lease arrangements are generally comprised of fixed lease payments and do not include options to purchase the underlying assets and to extend or terminate the lease.
Interest income for the year ended December 31, 2025 was immaterial.
For the year ended December 31, 2025, the Company recognized $43 of revenue from sales-type lease agreements and $36 cost of revenue. The Company’s short -term net investment in a lease receivable as of December 31, 2025 was $20 and is presented within trade receivables in the consolidated balance sheets. The Company’s long -term net investment in a lease receivable as of December 31, 2025 was $20 and is presented within long-term trade receivables in the consolidated balance sheets.
The following table illustrates the Group’s future sales-type lease receipts as of December 31, 2025:
| Year ending December 31, | ||||
| 2026 | $ | 20 | ||
| 2027 | 20 | |||
| Total future minimum receipts | $ | 40 | ||
ENVUE MEDICAL, INC.
Notes to Consolidated Financial Statements
(Amounts in thousands except share and per share data)
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Apr 15, 2026 | Showing above |
| 2024 | Mar 31, 2025 | |
| 2023 | Apr 8, 2024 | |
| 2022 | Apr 17, 2023 | |
| 2021 | Apr 15, 2022 | |
| 2020 | Apr 15, 2021 | |
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.